Evidence map›Paper›PMID 36590218›Full record

ArticleFrontiers in nutrition2022

Decreased circulating branched-chain amino acids are associated with development of Alzheimer's disease in elderly individuals with mild cognitive impairment.

Takeshi Ikeuchi, Mayuka Kanda, Hitomi Kitamura, Fumiyoshi Morikawa, Shuta Toru, Chika Nishimura, Kensaku Kasuga, Takayoshi Tokutake, Tetsuya Takahashi, Yasuko Kuroha and 20 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Metabolic Regulations ofMetabolites · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 15 institutions in 1 country.

Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Mayuka KandaResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Japan.
Hitomi KitamuraResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Japan.
Fumiyoshi MorikawaDepartment of Psychiatry, Asahikawa Keisenkai Hospital, Asahikawa, Japan.
Shuta ToruDepartment of Neurology, Nitobe Memorial Nakano General Hospital, Tokyo, Japan.
Chika NishimuraKurumi Clinic, Tokyo, Japan.
Kensaku KasugaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Takayoshi TokutakeDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Tetsuya TakahashiDepartment of Neurology, Nishiniigata Chuo Hospital, Niigata, Japan.
Yasuko KurohaDepartment of Neurology, Nishiniigata Chuo Hospital, Niigata, Japan.
Nobuhiko MiyazawaDepartment of Neurosurgery, Kofu Neurosurgical Hospital, Kofu, Japan.
Shin TanakaMishima Hospital, Niigata, Japan.
Kumiko UtsumiDepartment of Psychiatry, Sunagawa City Medical Center, Sunagawa, Japan.
Kenjiro OnoDivision of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Satoshi YanoDivision of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Tadanori HamanoFaculty of Medical Sciences, Second Department of Internal Medicine, University of Fukui, Fukui, Japan.
Satoshi NaruseDepartment of Neurology, Midori Hospital, Niigata, Japan.
Ryuji YajimaDepartment of Neurology, Midori Hospital, Niigata, Japan.
Noriko KawashimaKawashima Neurology Clinic, Fujisawa, Japan.
Chikako KanekoSouthern TOHOKU Medical Clinic, Koriyama, Japan.
Hisatsugu TachibanaDepartment of Neurology, Takatsuki General Hospital, Takatsuki, Japan.
Yuki YanoResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Japan.
Yumiko KatoResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Japan.
Sakino ToueResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Japan.
Hiroko JinzuInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Akihiko KitamuraResearch Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Yuri YokoyamaResearch Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Eiji KanekoInstitute of Education, Tokyo Medical and Dental University, Tokyo, Japan.
Minoru YamakadoDepartment of Nursing, Ashikaga University, Ashikaga, Japan.
Kenji NagaoResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Japan.
Ajinomoto (Japan) · JPNiigata University · JPNishi Niigata Chuo National Hospital · JPShowa University · JPTokyo Metropolitan Institute of Gerontology · JPAsahikawa City Hospital · JPAshikaga University · JPKurume University · JPNakano General Hospital · JPSouthern Tohoku General Hospital · JPSunagawa City Medical Center · JPTakatsuki General Hospital · JPTokyo Medical and Dental University · JPUniversity of Fukui · JPYamanashi Research Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nutritional epidemiology has shown that inadequate dietary protein intake is associated with poor brain function in the elderly population. The plasma free amino acid (PFAA) profile reflects nutritional status and may have the potential to predict future changes in cognitive function. Here, we report the results of a 2-year interim analysis of a 3-year longitudinal study following mild cognitive impairment (MCI) participants. Method: In a multicenter prospective cohort design, MCI participants were recruited, and fasting plasma samples were collected. Based on clinical assessment of cognitive function up to 2 years after blood collection, MCI participants were divided into two groups: remained with MCI or reverted to cognitively normal ("MCI-stable," Results: Plasma concentrations of all nine essential amino acids (EAAs) were lower in the AD-convert group. Among EAAs, three branched-chain amino acids (BCAAs), valine, leucine and isoleucine, and histidine (His) exhibited significant differences even in the logistic regression model adjusted for potential confounding factors such as age, sex, body mass index (BMI), and Conclusion: The PFAA profile, especially decreases in BCAAs and His, is associated with development of AD in MCI participants, and the difference was larger in the Clinical trial registration: [https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000025322], identifier [UMIN000021965].

Indexed as

APOEbiomarker discoveryMMSE–Mini-Mental State Examinationmulticenter clinical studyprotein malnutrition

Identifiers

PMID36590218
PMCPMC9794986
OpenAlexW4311367154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.